Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Chordoma 2Triple Negative Breast Neoplasms 1Sinonasal undifferentiated carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Melanoma 1HER2-positive Breast Cancer 1Fistula 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Squamous Cell 1Carcinoma, Mucoepidermoid 1Carcinoma, Adenoid Cystic 1

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 7Gemcitabine 6Epirubicin 6Cisplatin 6apatinib 5tislelizumab 4atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3toripalimab 2talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × Protons × Clear all
NCT05692661 2023-01-20

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Shanghai Proton and Heavy Ion Center

Phase 1 Unknown
24 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡